January 2025 – Page 2

Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment

3 months ago talkbio0Tagged AKAP9 protein, human, Clinical Equipoise, Clinical Trials, Pulmonary arterial hypertension, sotatercept-csrk, Winrevair

Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination

Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome

3 months ago talkbio0Tagged Clinical Research, Cognitive Improvement, EMPEROR, Infantile Severe Myoclonic Epilepsy, Phase 3 trial, regulatory, Seizures, Zorevunersen

Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment

J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

3 months ago talkbio0Tagged chemotherapy-free regimen, Epidermal Growth Factor Receptor, Lazcluze, Mutation, Non-Small Cell Lung Carcinoma, Overall Survival, Phase III MARIPOSA trial, Rybrevant, Tagrisso

Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen

New year starts with a bang as trio of venture financings brings in $382M

3 months ago talkbio0Tagged biotech, Capital, Investments, Life, Megarounds, Private financing, Tenvie, venture

Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

3 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study

3 months ago talkbio0Tagged Clinical Research, INAVO120, Inavolisib, Itovebi, Malignant neoplasm of breast, Overall Survival, PIK3CA mutation, Roche (company)

Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

3 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings

3 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, Chronic disease, Confirmation, Hearings, public health policy, Robert F. Kennedy, Secretary Nomination, Senate, Skepticism, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

3 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models

Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026

3 months ago talkbio0Tagged biopharmaceutical company, CEO, Christophe Weber, Drug Industry, Kim, Leadership, succession, Takeda, Transition Mutation

Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company